Want to see MAIA full AI Analyst Report?
MAIA Stock Chart & Stats
$1.28
$0.04(3.23%)
At close: 4:00 PM EDT
$1.28
$0.04(3.23%)
Day’s Range― - ―
52-Week Range$0.87 - $3.19
Previous Close$1.27
Volume359.59K
Average Volume (3M)570.23K
Market Cap
$76.00M
Enterprise Value$45.84M
Total Cash (Recent Filing)$34.41M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.40
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding60,800,760
10 Day Avg. Volume650,834
30 Day Avg. Volume570,232
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)20.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.61
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.08
Forecast
1Y Price Target
$14.00Price Target Upside993.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe promising results from the Phase 2 THIO-101 trial indicate a potential breakthrough in cancer treatment, enhancing MAIA's regulatory strategy and expediting FDA approval, which could significantly boost the company's market position and revenue potential.
Intellectual Property StrengthSecuring a European patent strengthens MAIA's intellectual property portfolio, providing a competitive advantage in the oncology market and protecting its proprietary technology, which is crucial for long-term revenue generation and market exclusivity.
Leadership StabilityEnhancing executive compensation packages aligns leadership incentives with corporate goals, ensuring stability and continuity in strategic direction, which is vital for navigating the complex biotech landscape and achieving long-term success.
Bears Say
Lack Of RevenueThe absence of revenue generation reflects the company's early-stage status and reliance on external funding, posing a risk to financial sustainability and limiting its ability to self-fund R&D and operational activities in the long term.
Negative Cash FlowConsistently negative cash flow underscores the company's dependency on external financing to maintain operations, which could lead to dilution of equity or increased debt, impacting financial flexibility and long-term viability.
Limited Financial FlexibilityLimited stockholders' equity restricts MAIA's financial flexibility, making it challenging to absorb operational shocks or invest in growth opportunities without seeking additional external funding, which could affect its competitive positioning.
MAIA Biotechnology, Inc. News
MAIA FAQ
What was MAIA Biotechnology, Inc.’s price range in the past 12 months?
MAIA Biotechnology, Inc. lowest stock price was $0.87 and its highest was $3.19 in the past 12 months.
What is MAIA Biotechnology, Inc.’s market cap?
MAIA Biotechnology, Inc.’s market cap is $76.00M.
When is MAIA Biotechnology, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MAIA Biotechnology, Inc.’s earnings last quarter?
MAIA Biotechnology, Inc. released its earnings results on Aug 19, 2024. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.415 by -$0.085.
Is MAIA Biotechnology, Inc. overvalued?
According to Wall Street analysts MAIA Biotechnology, Inc.’s price is currently Undervalued.
Does MAIA Biotechnology, Inc. pay dividends?
MAIA Biotechnology, Inc. does not currently pay dividends.
What is MAIA Biotechnology, Inc.’s EPS estimate?
MAIA Biotechnology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MAIA Biotechnology, Inc. have?
MAIA Biotechnology, Inc. has 60,800,760 shares outstanding.
What happened to MAIA Biotechnology, Inc.’s price movement after its last earnings report?
MAIA Biotechnology, Inc. reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.415. Following the earnings report the stock price went up 3.922%.
Which hedge fund is a major shareholder of MAIA Biotechnology, Inc.?
Currently, no hedge funds are holding shares in MAIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MAIA Biotechnology, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (993.75% Upside)
$14.00 (993.75% Upside)
Insider Transactions
Bought Shares
Worth $202.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
197.71%
Trailing 12-Months
Company Description
MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
MAIA Stock 12 Month Forecast
Average Price Target
$14.00
▲(993.75% Upside)
Technical Analysis
Veru
―
―
OnKure Therapeutics
―
Xilio Therapeutics
―
Radiopharm Theranostics Limited Sponsored ADR
―
Ownership Overview
8.54% Insiders
3.90% Mutual Funds
0.12% Other Institutional Investors
83.16% Public Companies and
Individual Investors